eLibrary:

Don't have Acrobat Reader?
Download it here

eLibrary:
Published Research/Articles

Cardiology

I-123 Studies on Various Diagnostic Applications

Radionuclide imaging in heart failure: Assessing etiology and outcomes and implications for management, James E. Udelson, MD, Colin D. Shafer, MD, and Ignasi Carrió, MD, Journal of Nuclear Cardiology Sept/Oct 2002 - Vol 9, #5;S40–S52

Radionuclide imaging in heart failure (PDF) radionuclide_imaging.pdf (this pdf can be found under Molecular Imaging/Cardiology)

Fatty Acid Metabolic Imaging with I-123-BMIPP for the Diagnosis of Coronary Artery Disease, Fujiwara et al, Journal of Nuclear Medicine, Jan '97, Vol 38 #1

MIBG Imaging, Patel, Amar, D. and Iskandrian, Ami, E, Journal of Nuclear Cardiology, 2002 Vol 9:75-94

Neurology

I-123 Studies on Various Diagnostic Applications

Test/Retest Reproducibility of Iodine-123-Β CIT SPECT Brain Measurement of Dopamine Transporters in Parkinson’s Patients, Seibyl et al, Journal of Nuclear Medicine, September 1997, Volume 38, #9

Effect of Haloperidol Dose on Iodine-123-IBZM Brain SPECT Imaging in Schizophrenic Patients, Vallabhajosula et al, Journal of Nuclear Medicine, Feb ‘97, Vol 38 #2

Imaging of Dopamine Transporters with Iodine-123-B CIT and SPECT in Parkinson’s Disease, Asenbaum et al, Journal of Nuclear Medicine, Jan ‘97, Vol 38 #1

Simplified Quantification and Reproducibility Studies of Dopamine D2-Receptor Binding with I-123-IBF SPECT in Healthy Subjects, Ichise et al, JNM, Jan ‘97 Vol 38 #1

Oncology

I-123 for Whole Body Diagnostic Thyroid Tumor Imaging

General References

  1. Cavalieri RR. Nuclear imaging in the management of thyroid carcinoma. Thyroid 6:485-491, 1996.
  2. Galloway RJ, Smallridge RC. Imaging in thyroid cancer. Endocrin Metab Clin N America 25:93-113, 1996.

    Stunning
  3. Jeevanram RK, Shah DH, Sharma SM, Ganatra RD. Influence of initial large dose on subsequent uptake of therapeutic radioiodine in thyroid cancer patients. Int J Rad Appl Instrum 13:277-279, 1986.
  4. Park HM, Perkins OW, Edmondson JW, Schnute RB, Manatunga A. Influence of diagnostic radioiodines on the uptake of ablative dose of iodine-131. Thyroid 4:49-54, 1994.
  5. Yagcloglu H, Ozalp E, Ibis E, Aras G. Partial stunning in thyroid remnant after administration of scanning dose followed by 100 mCi I-131 therapy. Clin Nucl Med 21:340, 1996.
  6. Huic D, Medvedec M, Dodig D, Popovic S, Ivancevic D, Pavlinovic Z, Zuvic M. Radioiodine uptake in thyroid cancer patients after diagnostic application of low-dose 131I. Nucl Med Commun 17:839-842, 1996.
  7. Park HM, Park YH, Zhou XH. Detection of thyroid remnant/metastasis without stunning: an ongoing dilemma. Thyroid 7:277-280, 1997.
  8. Muratet J, Daver A, Minier J, Larra F. Influence of scanning doses of Iodine-131 on subsequent first ablative treatment outcome in patients operated on for differentiated thyroid carcinoma. J Nucl Med 39:1546-1550, 1998.
  9. Leger FA, Izembart M, Dagousset F, Barritault L, Baillet G, Chevalier A, Clerc J. Decreased uptake of therapeutic doses of iodine-131 after 185-MBq iodine-131 diagnostic imaging for thyroid remnants in differentiated thyroid carcinoma. Eur J Nucl Med 25:242-6, 1998.
  10. Kao CH, Yen TC. Stunning effects after a diagnostic dose of iodine-131. Nuklearmedizin 37:30-32, 1998.
  11. Sabri O, Zimny M, Schreckenberger M, Meyer-Oelmann A, Reinartz P, Buell U. Does thyroid stunning exist? A model with benign thyroid disease. Eur J Nucl Med 27:1591-7, 2000.
  12. Yeung HW, Humm JL, Larson SM. Radioiodine uptake in thyroid remnants during therapy after tracer dosimetry. J Nucl Med 41:1082-5, 2000.
  13. Medvedec M. Thyroid stunning. J Nucl Med 42:1129-1131, 2001 (letter).
  14. Medvedec M, Grosev D, Loncaric S, Pavlinovic Z, Dodig D. As soon as possible is already too late. J Nucl Med 42:322P, 2001 (abstract).
  15. McDougall IR. 74 MBq radioiodine 131I does not prevent uptake of therapeutic doses of 131I (i.e. it does not cause stunning) in differentiated thyroid cancer. Nucl Med Commun 18:505-512, 1997.
  16. Cholewinski SP, Yoo KS, Klieger PS, O'Mara RE. Absence of thyroid stunning after diagnostic whole-body scanning with 185 MBq 131I. J Nucl Med 41:1198-1202, 2000.
  17. Chopra S, Wastie ML, Chan S, Vincent RM, Przeslak A, Perkins AC, Ubhi CS. Assessment of completeness of thyroid ablation by estimation of neck uptake of 131I on whole-body scans: comparison of quantification and visual assessment of thyroid bed uptake. Nucl Med Commun 17:687-691, 1996.
  18. McMenemin RM, Hilditch TE, Dempsey MF, Reed NS. Thyroid stunning after 131I diagnostic whole-body scanning. J Nucl Med 42:986, 2001 (letter).
  19. Morris LF, Waxman AD, Braunstein GD. The nonimpact of thyroid stunning: remnant ablation rates in 131I-scanned and nonscanned individuals. J Clin Endocrinol Metab 86:3507-3511, 2001.
  20. Park HM. The stunning effect in radioiodine therapy of thyroid cancer. In: Freeman L, ed., Nuclear Medicine Annals. Philadelphia, PA: Lippincott, Williams, & Wilkins: 2001: 49-67.

    Comparison of I-123 and I-131
  21. Naddaf S, Young I, Rapun R, et al. Comparison between Iodine-123 (I-123) and iodine-131 (I-131) sodium iodide total body scanning in thyroid cancer patients. J Nucl Med 37:251P, 1996 (abstract).
  22. Bautovich GJ, Towson JE, Eberl S, et al. Comparison of iodine-123 and iodine-131 as a scanning agent for the detection of metastatic thyroid cancer. J Nucl Med 38:150P, 1997 (abstract).
  23. Yaakob W, Gordon L, Spicer KM, Nitke SJ. The usefulness of iodine-123 whole-body scans in evaluating thyroid carcinoma and metastases. J Nucl Med Technol 27:279-81, 1999.
  24. Mandel SJ, Shankar LK, Bernard F, Yamamoto A, Alavi A. Superiority of iodine-123 compared with iodine-131 scanning for thyroid remnants in patients with differentiated thyroid cancer. Clin Nucl Med 26:6-9, 2001.
  25. Siddiqi A, Roley RR, Britton KE, Sibtain A, Plowman PN, Grossman AB, Monson JP, Besser GM. The role of 123I-diagnostic imaging in the follow-up of patients with differentiated thyroid carcinoma as compared to 131I-scanning: avoidance of negative therapeutic uptake due to stunning. Clin Endocrinol 55:515-521, 2001.
  26. Berbano R, Naddaf S, Echemendia E, Barsa J, Turoglu H, Akisik M, Abdel-Dayem HM, Young I. Use of iodine-123 as a diagnostic tracer for neck and whole-body scanning in patients with well-differentiated thyroid cancer. Endocrine Prac 4:11-16, 1998.
  27. Shankar LK, Yamamoto AJ, Alavi A, Mandel SJ. Comparison of 123I scintigraphy at 5 and 24 hours in patients with differentiated thyroid cancer. J Nucl Med 43:72-6, 2002.
  28. Gerard SK, Cavalieri RR. I-123 diagnostic thyroid tumor whole-body scanning with imaging at 6, 24, and 48 hours. Clin Nucl Med 27:1-8, 2002.
  29. Sarkar SD, Kalapparambath TP, Palestro CJ. Comparison of 123I and 131I for whole body imaging in thyroid cancer. J Nucl Med 43:632-634, 2002.

    Effects of Radioiodine Dose and Scanning Time

  30. Halpern SE, Preisman R. Hagan P. Scanning dose and the detection of thyroid metastases. J Nucl Med 20:1099-1100, 1979.
  31. Nemec J, Rohling S, Amarazil V et al. Comparison of the distribution of diagnostic and thyroablative I-131 in the evaluation of differentiated thyroid cancers. J Nucl Med 20:92-97, 1979.
  32. Coakley AJ, Page CJ, Croft D. Scanning dose and detection of thyroid metastases. J Nucl Med 21:803, 1980.
  33. Pacini F, Franceso L, Foramica N, Elisei R, Anelli S, Ceccarelli C, Pinchera A., Therapeutic doses of Iodine-131 reveal undiagnosed metastases in thyroid cancer patients with detectable serum thyroglobulin levels. J Nucl Med 28:1888-1891, 1987.
  34. Spies WG, Wojtowicz CH, Spies SM, Shah AY, Zimmer M. Value of post-therapy whole body I-131 imaging in the evaluation of patients with thyroid carcinoma having undergone high-dose I-131 therapy. Clin Nucl Med 14:793-800, 1989.
  35. Waxman A, Ramanna L, Chapman N et al. The significance of I-131 scan dose in patients with thyroid cancer: determination of ablation: concise communication. J Nucl Med 22:861-865, 1981
  36. Khan S, Waxman A, Nagaraj N, Braunstein G. Optimization of post ablative I-131 scintigraphy: comparison of 2 day vs. 7 day post therapy study study in patients with differentiated thyroid cancer (DTC). J Nucl Med 35:15P, 1994 (abstract).
  37. Sarkar SD, Afriyie MO, Palestro CJ. Recombinant human thyroid-stimulating hormone-aided scintigraphy. Comparison of imaging at multiple times after I-131 administration. Clin Nucl Med 26:392-395, 2001.

    Dosimetry of I-123 versus I-131

  38. Stabin MG, Stubbs JB, Toohey RE. Radiation dose estimates for radiopharmaceuticals. Radiation Internal Dose Information Center, Oak Ridge Institute for Science and Education, Oak Ridge, TN 37831-0117. NUREG/CR-6345. April, 1996.

Sterilization

Technical Publications

Connections Newsletter

Jan. 2006

Connections Newsletter Archives

2005

2004

2003

2001

2000